STOCKHOLM, April 15, 2024 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France, reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701..

斯德哥尔摩，2024年4月15日/PRNewswire/--Medivir AB（纳斯达克：MVIR）（斯德哥尔摩：MVIR），一家专注于在医疗需求高度未满足的领域开发癌症创新治疗的制药公司，今天宣布其合作伙伴Vetbiolix，一家总部位于法国的兽医生物技术公司，报告了其候选药物VBX-1000（以前称为MIV-701）在狗牙周病方面的概念验证临床研究的积极结果。。

VBX-1000 (MIV-701) is the first specific cathepsin-K inhibitor, for the treatment of periodontal disease in dogs. During the early development of a selective cathepsin-K inhibitor, MIV-701 was discovered to have properties suitable for non-human animal use and it was out-licensed to Vetbiolix in 2019 to explore clinical utility in non-human animal..

VBX-1000（MIV-701）是第一种特异性组织蛋白酶K抑制剂，用于治疗狗的牙周病。在选择性组织蛋白酶K抑制剂的早期开发过程中，发现MIV-701具有适合非人类动物使用的特性，并于2019年获得Vetbiolix的许可，以探索其在非人类动物中的临床应用。。

In the study conducted by Vetbiolix, the drug was well tolerated and the primary efficacy endpoint was met, achieving a statistically significant reduction of the plasma biomarker for bone degradation (CTX1). Vetbiolix is now working with experts in the field to set up a regulatory Pilot clinical study to further strengthen the demonstration of the effects of VBX-1000 (MIV-701) in a double blind, randomized, placebo-controlled clinical trial in dogs..

在Vetbiolix进行的研究中，该药物耐受性良好，达到了主要疗效终点，实现了骨降解血浆生物标志物（CTX1）的统计学显着降低。Vetbiolix目前正在与该领域的专家合作，建立一项监管试点临床研究，以进一步加强VBX-1000（MIV-701）在狗的双盲，随机，安慰剂对照临床试验中的效果证明。。

As part of the agreement with Vetbiolix, Medivir is entitled to minor development and regulatory milestone payments with value upside potential coming from future royalty payments on net sales and/or share of partnering payments received by Vetbiolix in case of future partnering transactions with VBX-1000..

作为与Vetbiolix协议的一部分，Medivir有权获得较小的开发和监管里程碑付款，这些付款具有价值上升潜力，来自Vetbiolix在未来与VBX-1000进行合作交易时收到的净销售额和/或合作付款份额的未来特许权使用费。。

-  'Partnering and collaborations are important parts of Medivir's business model to accelerate the development of all assets and reduce financial risk. MIV-701 is another example of the company's ability and track-record in out-licensing to generate additional value for shareholders. The positive results of the Proof-of-Concept study are also a testament to the quality of research performed by Medivir and add yet another molecule to the number of candidates that have been shown to provide clinical benefit,' says Jens Lindberg, Chief Executive Officer at Medivir..

-“合作和协作是Medivir商业模式的重要组成部分，可以加速所有资产的开发并降低财务风险。MIV-701是该公司为股东创造附加价值的能力和进出许可记录的另一个例子。Medivir首席执行官延斯·林德伯格（Jens Lindberg）说，概念验证研究的积极结果也证明了Medivir进行的研究质量，并为已被证明具有临床益处的候选人数量增加了另一个分子。。

For additional information, please contact;

有关更多信息，请联系；

Magnus Christensen, CFO, Medivir AB

Magnus Christensen，Medivir AB首席财务官

Telephone: +46 8 5468 3100.

电话：+46 8 5468 3100。

E-mail: magnus.christensen@medivir.com

电子邮件：magnus.christensen@medivir.com

About Medivir

关于Medivir

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects.

Medivir开发创新药物，重点关注未满足医疗需求的癌症。候选药物针对可用疗法有限或缺失的适应症领域，并且有很大的机会为患者提供显着改善。Medivir专注于开发fostroxacitabine bralpamide（fostrox），这是一种智能的靶向化疗，旨在选择性治疗肝癌细胞并尽量减少副作用。

Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com. .

合作和伙伴关系是Medivir商业模式的重要组成部分，药物开发由Medivir或合伙进行。Medivir的股票（股票代码：MVIR）在纳斯达克斯德哥尔摩的小盘股名单上上市。www.medivir.com。

About Vetbiolix

关于Vetbiolix

Vetbiolix develops innovative products for the treatment and prevention of diseases affecting pets. Vetbiolix has built a unique pipeline of First-in-class small molecules in-licensed (exclusive and worldwide license) from Human Biotech worldwide which will answer to veterinary unmet medical needs in periodontitis, osteoarthritis and gut motility disorders.

Vetbiolix开发创新产品，用于治疗和预防影响宠物的疾病。Vetbiolix已在全球人类生物技术公司（Human Biotech worldwide）的许可（独家和全球许可）中建立了一条独特的一流小分子管道，该管道将满足兽医在牙周炎，骨关节炎和肠道运动障碍方面未得到满足的医疗需求。

Vetbiolix focuses exclusively on clinical developments of its drug candidates: the company invests on (i) clinical proof of concept studies, (ii) CMC-Pharmaceutical developments, (iii) regulatory Pilot clinical studies and (iv) regulatory Pivotal clinical studies. Revenue generation of the company will be based on out-licensing and/or co-developments deals with the Veterinary Pharmaceutical Industry www.vetbiolix.com..

Vetbiolix专注于其候选药物的临床开发：该公司投资于（i）临床概念验证研究，（ii）CMC药物开发，（iii）监管试点临床研究和（iv）监管关键临床研究。该公司的创收将基于与兽药行业的外部许可和/或共同开发交易www.vetbiolix.com。。

This information was brought to you by Cision http://news.cision.com

此信息由Cision提供给您http://news.cision.com

https://news.cision.com/medivir/r/medivir-s-partner-vetbiolix-announces-positive-results-from-proof-of-concept-study-with-vbx-1000--pr,c3961646

https://news.cision.com/medivir/r/medivir-s-partner-vetbiolix-announces-positive-results-from-proof-of-concept-study-with-vbx-1000--pr，c3961646

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/652/3961646/2731714.pdf

https://mb.cision.com/Main/652/3961646/2731714.pdf

Press release (PDF)

新闻稿（PDF）

View original content:https://www.prnewswire.com/news-releases/medivirs-partner-vetbiolix-announces-positive-results-from-proof-of-concept-study-with-vbx-1000-previously-known-as-miv-701-302116699.html

查看原始内容：https://www.prnewswire.com/news-releases/medivirs-partner-vetbiolix-announces-positive-results-from-proof-of-concept-study-with-vbx-1000-previously-known-as-miv-701-302116699.html

SOURCE Medivir

来源Medivir

Company Codes: Bloomberg:MVIR@SS, ISIN:SE0020181014, RICS:MVIR.ST, Stockholm:MVIR

公司代码：彭博社：MVIR@SS，ISIN:SE0020181014，RICS:MVIR。斯德哥尔摩ST：MVIR